---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-213940"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:20:23.960571+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Soleno Therapeutics appoints Matthew Pauls to Board, expanding to seven directors

## Summary
- Board increased to seven; Matthew Pauls appointed as Class II director effective August 15, 2023, term expiring 2026.
- Pauls brings 30+ years biopharma experience; currently CEO of Savara Inc. (NASDAQ: SVRA) and former CEO of Strongbridge Biopharma.
- Granted option for 15,000 shares vesting monthly over 4 years under the Company's 2014 equity plan.
- Appointment comes as Soleno advances DCCR for Prader-Willi syndrome toward planned regulatory filing and potential approval.

## SEC filing metadata
- accession: 0001193125-23-213940
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/0001193125-23-213940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/d523594d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-213940
- JSON: https://secwatch.observer/filing/0001193125-23-213940.json
- Plain text: https://secwatch.observer/filing/0001193125-23-213940.txt

## Key facts
- Executive change
  Matthew Pauls was appointed as Director at SOLENO THERAPEUTICS INC.
  - Action: appointed
  - Role: Director
  source text: appointed Mr. Matthew Pauls to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/0001193125-23-213940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.